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Genetic and Proteomic Features Associated with Survival
after Treatment with Erlotinib in First-Line Therapy of
Non-small Cell Lung Cancer in Eastern Cooperative
Oncology Group 3503
Joseph M. Amann, PhD,* Ju-Whei Lee, PhD,† Heinrich Roder, PhD,‡ Julie Brahmer, MD,§
Adriana Gonzalez, MD, Joan H. Schiller, MD,¶ and David P. Carbone, MD, PhD*#**
Introduction: Serum proteomics and mutations in the epidermal
growth factor receptor (EGFR) and KRAS have been associated with
benefit after therapy with EGFR-targeted therapies in non-small cell
lung cancer, but all three have not been evaluated in any one study.
Hypothesis: Pretreatment serum proteomics predicts survival in
Western advanced non-small cell lung cancer patients with wild-
type EGFR and independent of KRAS mutation status.
Methods: We analyzed available biospecimens from Eastern Coop-
erative Oncology Group 3503, a single-arm phase II study of
erlotinib in first-line advanced lung cancer, for proteomics signa-
tures in the previously described serum matrix-assisted laser desorp-
tion ionization proteomic classifier (VeriStrat) as well as for KRAS
and EGFR mutations.
Results: Out of 137 enrolled patients, analyzable biologic samples
were available on 102. Nine of 41 (22%) demonstrated KRAS
mutations and 3 of 41 (7%) harbored EGFR mutations. VeriStrat
classification identified 64 of 88 (73%) as predicted to have “good”
and 24 of 88 (27%) predicted to have “poor” outcomes. A statisti-
cally significant correlation of VeriStrat status (p  0.001) was
found with survival. EGFR mutations, but not KRAS mutations, also
correlated with survival.
Conclusions: The previously defined matrix-assisted laser desorp-
tion ionization predictor remains a potent and highly clinically
significant predictor of survival after first-line treatment with erlo-
tinib in patients with wild-type EGFR and independent of mutations
in KRAS.
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One of the most significant advancements in lung cancertherapy over the last decade has been the introduction of
epidermal growth factor receptor (EGFR)-targeted therapies.
The efficacy of small molecule tyrosine kinase inhibitors
(TKIs), erlotinib and gefitinib, and antibodies, cetuximab and
panitumumab, have been examined in clinical trials as first-,
second-, and later-line agents, alone or in combination with
standard cytotoxic chemotherapeutics.1–8 Significant survival
benefits have been seen for small molecule EGFR-TKIs in
non-small cell lung cancer (NSCLC) in these trials, despite
low objective response rates (RRs). Importantly, in the ran-
domized clinical trial BR.21, erlotinib showed an increased
overall survival (OS) in NSCLC over placebo,3 and in the
IRESSA non-small cell lung cancer (NSCLC) Trial Evaluat-
ing REsponse and Survival against Taxotere (INTEREST)
trial, it showed equivalence to second-line chemotherapy,9
both in unselected patients.
Molecular characterization of tumors from clinical tri-
als has provided important information regarding potential
biomarkers and their correlation with response to small mol-
ecule inhibitors. These retrospective analyses of patient sam-
ples from clinical trials have shown that EGFR-activating
mutations are very highly correlated with RR and with OS and
time to progression (TTP) regardless of therapy.10–15 Another
genetic factor that has been reported to predict better RR and OS
is high polysomy/amplification for the EGFR locus.16 However,
EGFR protein expression, as determined by immunohistochem-
istry, is only marginally predictive if at all.17,18 The presence of
a mutation in the KRAS gene has been associated with a lack of
response to EGFR inhibition therapy and is used by many
groups to select patients against therapy with EGFR-targeted
agents. This is especially true in the treatment of colorectal
cancer (CRC) with the monoclonal antibodies cetuximab and
panitumumab.19–21 Several retrospective studies in NSCLC
have reported similar results with regard to response to small
molecule TKIs and KRAS status, as reviewed in Ref. 21. Al-
though most of these biomarkers predict response, their predic-
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tive value for survival is much less clear. In addition, all the
above tests are assayed on tumor biopsy material, which is not
only difficult to get in a large fraction of cases but also highly
prone to artifacts related to the heterogeneity within a tumor and
between primary tumor sites and metastases.22–24
In a recent article, we have shown that a classifier based
on matrix-assisted laser desorption ionization time of flight mass
spectrometry of pretreatment serum can predict outcome of
patients taking erlotinib or gefitinib.25 Our analysis is based on a
fixed and reproducible assay that examines eight protein peaks
in spectra that are derived from 1 l of serum or plasma.
Although the identity of most of these peaks is known, they
seem to have posttranslational modifications that are still under
investigation (data not shown). To assess the value of our
predictor in the context of the EGFR and KRAS mutation status
of the tumor, we have analyzed these mutations in the cooper-
ative group study E3503. Using updated clinical data, we again
confirmed the prognostic value of VeriStrat and EGFR muta-
tions in both TTP and OS in this single-arm study. KRAS
mutations, however, lacked any association with either.
PATIENTS AND METHODS
Selection of Patients and Treatment
The eligibility criteria for Eastern Cooperative Oncol-
ogy Group (ECOG) 3503 were for patients with confirmed
advanced (stage IIIB with pleural effusion or stage IV or
recurrent disease) NSCLC, with no history of prior chemo-
therapy or targeted therapy for metastatic disease and good
organ function, with a performance status of 0 to 2. Patients
were enrolled from September 2004 to August 2005 and
treatment consisted of erlotinib, 150 mg/d with clinical eval-
uations every 4 weeks, and was continued until progressive
disease, unacceptable toxicity, or withdrawal. Tumor mea-
surements were made every 8 weeks.
Tumor Samples and DNA Isolation
Tumor tissue was obtained from ECOG as formalin-fixed
paraffin-embedded tissue in 10-M-thick sections on glass
slides. The percentage tumor and areas of highest tumor content
were identified in hematoxylin and eosin-stained slides and
marked by a trained pathologist specializing in classification of
lung tumors. The corresponding areas were marked on unstained
slides containing adjacent sections and microdissected from the
tumor tissue using a scalpel blade. DNA was isolated from the
tumor tissue by placing the scrapings from the slide directly into
a 1.5-ml microcentrifuge tube containing 50 l of a solution of
25 mM sodium hydroxide and 0.2 mM ethylenediaminetetraace-
tic acid. The tube was placed into a heating block at 95°C for 20
minutes with occasional vortexing. Neutralization was per-
formed by removing the tube from the heat and adding an equal
volume of 40 mM Tris hydrochloric acid. The tube was micro-
centrifuged for 5 minutes at maximum speed to pellet undigested
material and 2 to 4 l of sample removed for polymerase chain
reaction (PCR).
PCR for EGFR Exons 19 and 21 and for KRAS
Exon 2
PCR products were generated using the following prim-
ers: exon 19 outside primers Exon19F (5-CCAGATCACT-
GGGCAGCATGTGGCACC-3) and Exon19R (5-AGCAG-
GGTCTAGAGCAGAGCAGCTGCC-3) and inside primers
Exon19intF (5-CCATCTCACAATTGCCAGTTA-3) and
Exon19intR (5-TGCCAGACATGAGAAAAGGTG-3). For
exon 21, outside primers Exon21F (5-CTAACGTTCGC-
CAGCCATAAGTCC-3) and Exon21R (5-GCTGCGAGCT-
CACCCAGAATGTCTGG-3) and inside primers Exon21intF
(5-CAGCCATAAGTCCTCGACGTGG-3) andExon21intR (5-
CATCCTCCCCTGCATGTGTTAAAC-3) were used. KRAS
primers included the outside primers KrasF (5-GTACT-
GGTGGAGTATTTGAT-3) and KrasR (5-TGAAAATG-
GTCAGAGAAACC-3) and the internal primers KrasintF
(5-GTATTAACCTTATGTGTGACA-3) and KrasintR (5-
GTCCTGCACCAGTAATATGC-3). Conditions for the EGFR
exon 19 and 21 reactions were 95°C (5 minutes) followed by 30
rounds of 95°C (45 seconds), 60°C (45 seconds), and 72°C
(45 seconds) and 1 round of 72°C (10 minutes). KRAS PCR
conditions were the same except for the annealing tempera-
ture, which was 52°C. PCR products were purified with a
PCR purification kit (Qiagen, Valencia, CA) and sequenced
directly with the internal PCR primers by submitting purified
samples to GenePass, Inc. (Nashville, TN).
Proteomic Analysis
The preparation of the serum samples for proteomic
analysis and description of the VeriStrat predictor are re-
ported in Ref. 25.
Statistical Analysis
This analysis was based on ECOG 3503 data pulled on
April 27, 2009. Response was evaluated using RECIST
criteria. The objective RR was defined as the proportion of
patients with either a complete response or a partial response
among all analyzable patients. Patients who were unevaluable
or unknown for response were included in the denominator
when computing this rate. The disease control rate was
defined similarly as the objective RR except patients with
stable disease (SD) were included in the numerator rather
than in the denominator. OS was defined as the time from
registration to death from any cause. Patients who were alive
at the time of this analysis were censored at the date last
known alive. TTP was defined as the time from registration to
first documentation of disease progression (per RECIST).
Patients without documented progression were censored at
the time of last known free of progression.
Descriptive statistics were used to characterize patient
demographics and disease characteristics. Exact binomial 90%
confidence intervals (CIs) were computed for the objective RR.
The difference in RR or disease control rate between EGFR/
KRAS mutation status was examined by Fisher’s exact test. The
Kaplan-Meier method was used for event-time distributions.
The OS and TTP curves between groups were compared using
log-rank tests. The association of biomarkers with survival was
evaluated in univariate analyses and multivariate analyses using
Cox proportional hazards regression modeling. All p values are
two-sided. Model building techniques were used in four steps
relying first on univariate testing for each biomarker. Biomark-
ers with statistical significance 0.2 were considered for the
next step of model building. Backward elimination, forward
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selection, and stepwise selection (with p  0.2) were then
performed on biomarkers to select possible models. At the final
stepwise step, two-way interactions under the hierarchical prin-
ciple were added into the model as well for considerations. The
proportional hazards assumption of each covariate was evalu-
ated after model building using time-by-covariate interactions.
Model fitting was assessed via the Cox-Snell generalized
residuals plot and diagnostics for influential points. A level
of 5% was considered statistically significant unless spec-
ified otherwise.
RESULTS
Patient Population
Of the 137 patients enrolled in ECOG 3503, 102
patients (excluding those with definitely ineligible status) had
analyzable biologic samples (Table 1). Table 2 shows the
demographics and disease characteristics of these 102 pa-
tients. The median age was 70 years with a range of 41 to 93
years. The majority of the patients were women (57.8%) and
whites (92.2%), with African American and Asian compris-
ing 5.9% and 2.0%, respectively. Most of the patients enter-
ing the study were stage IV, not recurrent (70.6%) with
multiple metastatic sites. Most (94.1%) had not received any
TABLE 1. Distribution of Proteomics and Mutation Data
N (Out of 137
Enrolled Patients)
N (Out of 102
Analyzable Patients)
Veristrat results
Missing 44 14
Poor 25 24
Good 68 64
Exon 19
Missing 94 61
Wild type 43 41
Exon 21
Missing 94 61
Mutation 3 3
Wild type 40 38
KRAS
Missing 94 61
GTT (12) 1 1
TGC (13) 2 2
TGT (12) 7 6
Wild type 33 32
Tumor (%)
Missing 94 61
30 4 4
40 4 4
50 4 4
60 8 8
70 5 4
80 5 5
85 2 2
90 9 8
95 1 1
100 1 1
TABLE 2. Patients Demographics and Disease
Characteristics
N (%)
Sex
Male 43 (42.2)
Female 59 (57.8)
Race
White 94 (92.2)
Black 6 (5.9)
Asian 2 (2.0)
Ethnicity
Unknown 4 (3.9)
Non-Hispanic 97 (95.1)
Institution refusal 1 (1.0)
Performance status
0 29 (28.4)
1 47 (46.1)
2 26 (25.5)
Weight loss in previous 6 mo (%)
5 69 (67.6)
5–10 16 (15.7)
10–20 14 (13.7)
20 3 (2.9)
Disease stage at entry
IIIB (not recurrent) 8 (7.8)
IV (not recurrent) 72 (70.6)
Recurrent 22 (21.6)
Histology
Squamous carcinoma 11 (10.8)
Adenocarcinoma 66 (64.7)
Large-cell carcinoma 1 (1.0)
Bronchoalveolar carcinoma 2 (2.0)
Non-small cell lung cancer, NOS 17 (16.7)
Combined/mixed 2 (2.0)
Other 3 (2.9)
Pleural effusion present
No 63 (61.8)
Yes, clinical assessment only 22 (21.6)
Yes, but cytologically negative 1 (1.0)
Yes, cytologically malignant 16 (15.7)
Metastatic sites
No metastatic sites 1 (1.0)
Single site 11 (10.8)
Multiple sites 90 (88.2)
Prior chemotherapy 6 (5.9)
Prior hormonal therapy 1 (1.0)
Prior radiation therapy 22 (21.6)
Prior surgery 33 (32.4)
Other prior therapy
Missing 6 (5.9)
Single other prior therapy 1 (1.0)
Not applicable (no therapy) 95 (93.1)
Age
Median (range) 70 (41–93)
NOS, not otherwise specified.
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prior chemotherapies for recurrent or metastatic disease. Six
of the 102 had previous adjuvant chemotherapy.
Basic Overall Clinical Outcomes
The median OS by all analyzable patients (102) was 7.9
months (95% CI: 5.5–11.7 months) (Figure 1A), whereas the
median TTP for these patients was 3.1 months (95% CI: 1.9–3.8
months) (Figure 1B). Seven of these patients had an objective
response (two complete responses and five partial responses)
(6.9%; 90% CI: 3.3–12.5%), 32 had SD (31.4%), and 39
progressed (38.2%) as the best overall response. For the remain-
ing 24 patients, the response was either unknown (n  3) or
unevaluable (n  21).
EGFR Mutation Status
Seventy-one tumor samples were obtained from ECOG
3503 enrolled patients in the form of formalin-fixed paraffin-
embedded tissue sections on glass slides. Using adjacent
hematoxylin and eosin-stained sections, the areas containing
tumor were marked and the percentage of tumor determined.
Of those 71 slides, there were 23 that contained too little
tumor to be analyzed. For our analysis, we focused our
attention on EGFR exons 19 and 21 as these two exons
comprise the majority, approximately 90%, of the known
mutations in EGFR.13 Of the 48 slides for which DNA was
isolated, PCR products for either exon 19 or 21 could not be
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FIGURE 1. Kaplan-Meier analysis showing (A) overall survival and (B) time to progression for all analyzable patients.
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obtained for five samples, even after multiple attempts.
Among the 43 tumor samples for which PCR products were
obtained (Table 1), we found no exon 19 mutations, but we
did find three exon 21 mutations (7%).
Response data was available on 41 analyzable patients
for whom EGFR mutation status was determined (Table 1).
Of these, the three patients with EGFR mutation fell into the
SD category (Table 3). Though no difference in objective RR
was observed between patients with mutant EGFR and wild-
type EGFR (0.00 versus 0.03, respectively), a significant
difference in disease control rate was observed (1.00 versus
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FIGURE 2. Kaplan-Meier analysis showing (A) overall survival and (B) time to progression by exon 21 mutation.
TABLE 3. Overall Response by Exon 21
Best Overall Response
Exon 21
Mutation, N Wild Type, N Total, N
Unknown 1 1
Partial response 1 1
Stable disease 3 12 15
Progression 19 19
Unevaluable 5 5
Total 3 38 41
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0.34, p  0.05). Although the median OS of these patients
was better than the median of those patients with wild-type
EGFR (33.0 versus 6.0 months), the increase in OS was
nearly statistically significant with a p value of 0.054 due to
the small sample size (Figure 2A). The TTP of these three
patients was also better than the patients with wild-type
EGFR (13.1 versus 1.8 months, p  0.052) (Figure 2B).
KRAS Mutation Status
Of the 41 analyzable patients for whom KRAS exon 2
mutation status was performed, nine mutations were found
(22%), which agrees with what has been reported previously
in the literature for NSCLC (Table 1). Three of these patients
had stable disease, five patients had progressive disease, and
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FIGURE 3. Kaplan-Meier analysis showing (A) overall survival and (B) time to progression by KRAS mutation.
TABLE 4. Overall Response by KRAS
Best Overall
Response
KRAS
GTT (12),
N
TGC (13),
N
TGT (12),
N
Wild Type,
N
Total,
N
Unknown 1 1
Partial response 1 1
Stable disease 3 12 15
Progression 1 1 3 14 19
Unevaluable 1 4 5
Total 1 2 6 32 41
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one patient was unevaluable for best overall response (Table
4). No difference in objective RR was found between patients
with mutant KRAS and wild-type KRAS nor was there any
difference in the disease control rate between the two groups.
The Kaplan-Meier plots of OS and TTP indicate that there is
no correlation of these clinical parameters with the KRAS
status of the tumor (Figures 3A, B).
VeriStrat Classification
Of 88 patients (out of 102 analyzable patients) with
VeriStrat results, 64 were classified as VeriStrat “good” and
24 were “poor.” Patients with “good” VeriStrat score are
expected to have a better OS or TTP than their counterparts.
Using updated OS and TTP from that reported previously,25
highly statistically significant differences between the two
FIGURE 4. Kaplan-Meier analysis showing (A) overall survival and (B) time to progression as determined by matrix-assisted
laser desorption ionization (MALDI).
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groups were maintained (Figures 4A, B; p  0.001 and p 
0.019, respectively).
Serum was available for all three patients whose tumors
contained EGFR mutations. Two (67%) were identified as
VeriStrat “good” and one (33%) was identified as VeriStrat
“poor.” In contrast, serum was available for 24 of 38
patients with wild-type EGFR. Seventeen (71%) were
identified as VeriStrat “good” and seven (29%) were
identified as VeriStrat “poor.”
Of the six sera available from patients with KRAS
mutant tumors, VeriStrat predicted that five (83%) belonged
in the “good” group, whereas only one (17%) was assigned to
the “poor” group. The median OS and TTP of the five
patients assigned to the “good” group were 12.6 months (95%
CI: 5.2– months) and 1.7 months (95% CI: 1.0–31.5
months), respectively. The one patient assigned to the poor
group had an OS of 4.3 months and a TTP of 1.7 months. Of
the 21 (out of 32) patients with wild-type KRAS who also had
serum data available, 14 (67%) were in the “good” group and
7 (33%) were assigned to the “poor” group. EGFR and KRAS
mutations did not correlate with VeriStrat status, but the
power of this observation for EGFR mutations is limited by
the small number in the analyzed sample set.
Table 5 presents results from univariate and multivar-
iate Cox regression analysis with VeriStrat results, EGFR
mutation status, and KRAS mutation status as explanatory
variables for OS and TTP, separately or jointly. For OS, as
suggested by the univariate models, a patient with VeriStrat
results  good has a risk of death that is 0.36 times that of a
patient whose VeriStrat results  poor (p  0.001) and a
patient with EGFR mutation has a risk that is 0.27 times that
of a patient with a wild-type EGFR (p 0.07). No difference
in hazard of death exists between patients with KRAS muta-
tion and those without KRAS mutation. The multivariate
model indicates that both EGFR status and VeriStrat results
nearly achieve statistical significance in predicting OS. Based
on this model, a patient with VeriStrat results  good has a
risk that is 0.44 times that of a patient whose VeriStrat
results  poor (p  0.07) while holding EGFR mutation
status constant. In addition, a patient with EGFRmutation has
a risk that is 0.26 times that of a patient with a wild-type
EGFR (p  0.08) while holding VeriStrat results constant.
For TTP, as suggested by the univariate models, a patient
with VeriStrat results  good has about half risk of a patient
whose VeriStrat results  poor (p  0.02) and a patient with
EGFR mutation has a risk that is about one-third of a patient
with a wild-type EGFR (p  0.06). No difference in hazard
of progression was observed between patients with KRAS
mutation and those without KRAS mutation. No multivariate
model was successfully fitted for TTP.
All these results imply that both EGFR mutation status
and VeriStrat are predictors for OS and TTP, and that KRAS
is not useful.
DISCUSSION
In the past, treatment decisions for patients were based
on the tumor’s organ of origin and light microscopic appear-
ance. With the discovery and increasing understanding of the
importance of patterns of genetic abnormalities in tumors,
and the development of agents designed to target the dereg-
ulated pathways resulting from these lesions, a polar opposite
thinking began to emerge. That is, all therapeutic decisions
should be driven by an understanding of these acquired
lesions, and their organ context was irrelevant. In this study,
we provide evidence that a middle path may in fact be the
best, and the impact of these lesions may be highly dependent
on tissue context.
Molecular analyses of multiple large clinical trials for
NSCLC and CRC using EGFR inhibitors have made it clear
that molecular features are important in predicting response
to EGFR inhibition therapy. In CRC, for example, patients
positive for EGFR protein expression are routinely being
treated with cetuximab or panitumumab as a single agent or
in combination with standard cytotoxic therapies,26 and these
agents have shown activity in NSCLC as well.27 In colon
cancer, analysis of several large trials has determined that
clinical benefit from the regimen was highly dependent on
having a wild-type KRAS gene.19–21,28 In fact, in one random-
ized phase III study looking at the addition of cetuximab to a
regimen of bevacizumab, oxaliplatin, and capecitabine for
CRC, analysis of tumors showed that the presence of a KRAS
mutation was associated with decreased TTP and worse
quality of life with these agents.29 These data were so pow-
erful that it is now widely accepted that testing for this
mutation is essential before prescribing these therapies.
In NSCLC, there are many studies showing activity
of EGFR-targeted therapies. Unlike CRC, however, a rel-
atively high percentage of NSCLC tumors contain muta-
tions in EGFR.10–12 Tumors with these mutations typically
occur in never smokers or light smokers and are more
common in Asian patients and women. Tumors with a mutant
TABLE 5. Outcomes from Univariate and Multivariate Models on Overall Survival and Time to Progression
Model n Predictor(s)
OS TTP
HR 95% CI p HR 95% CI p
Univariate model 88 VeriStrat 0.36 0.21–0.60 0.001 0.51 0.28–0.90 0.02
41 EGFR 0.27 0.06–1.13 0.07 0.31 0.09–1.06 0.06
41 KRAS 1.02 0.47–2.24 0.96 0.96 0.41–2.23 0.92
Multivariate model 27 EGFR 0.26 0.06–1.16 0.08
VeriStrat 0.44 0.18–1.08 0.07
OS, overall survival; HR, hazard ratio; TTP, time to progression; CI, confidence interval; EGFR, epidermal growth factor receptor.
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EGFR have very high RRs to TKIs, leading to the initiation
of prospective trials selecting patients for erlotinib therapy
based on the presence of an EGFR mutation.30–32 CRC and
NSCLC tumors both harbor frequent KRAS mutations, and
there are data that NSCLC tumors with mutant KRAS do not
respond to erlotinib or gefitinib therapy and, based on this and
the data in CRC, screening for mutations in KRAS has been
proposed for selection of patients who should not receive
therapy with EGFR-targeted therapies.14–16,21,28,33–35
Other molecular features are being proposed for the
selection of patients for therapy with these inhibitors. In a
previous study, we developed a classification algorithm based
on matrix-assisted laser desorption ionization-generated pro-
tein peaks from pretreatment serum or plasma that would
allow identification of patients with a higher likelihood of
survival benefit from erlotinib or gefitinib therapy.25 One of
the validation cohorts previously reported for this classifier
was from the multicenter cooperative group trial of erlotinib
as first-line therapy in advanced NSCLC.25 This classifier has
been commercialized with the trade name of VeriStrat, and
this classification was found to be independent of clinical
features, such as smoking, sex, and histology, that are usually
associated with response to the EGFR-TKIs. In addition, the
algorithm was predictive and not just prognostic, as it did not
classify patients for good or poor outcomes when treated with
standard chemotherapy or surgery alone but it did for patients
treated with erlotinib or gefitinib. However, it is possible that
this classifier was simply identifying patients with KRAS
mutant tumors, and in light of the CRC data, we felt it was
important to answer this question.
In this study, we used significantly updated clinical data
from E3503 to reanalyze the survival association of classifi-
cation of these patients using VeriStrat and analyzed all the
available tumor samples for EGFR and KRAS mutations. Of
the available tumor samples, we found three EGFR mutations
(7%) and nine KRAS mutations (22%). These frequencies
of EGFR and KRAS mutations agree with other studies in
NSCLC. Our results showed that for VeriStrat, the survival
prediction using updated clinical data was even better than
reported previously, and as expected, that survival and TTP
were also associated with EGFR mutations. KRAS status,
however, showed no correlation with outcome.
We then evaluated how the classifier results correlated
with EGFR and KRASmutation status. Of the available tumor
samples for which VeriStrat results and mutation status were
known, two of the three EGFR mutant tumors were classified
as good and one classified as poor, and five of the six patients
with a KRAS mutation and serum available were classified as
VeriStrat “good.” These results, and the KRAS survival data,
suggest that the prediction made by the algorithm is indepen-
dent of EGFR and KRAS status, although the confidence of
this conclusion for EGFR mutations is limited by the small
number of mutations in this cohort. We look forward to
confirmation of these findings when the KRAS analysis of
several large studies evaluating cetuximab in lung cancer
(e.g., BMS 099, FLEX, and SWOG 0342) are published.
Preliminary data presented in abstract form support our con-
clusions. Thus, there may be a subset of NSCLC patients with
KRAS mutations who will benefit from EGFR-TKI therapy
and VeriStrat may be capable of identifying those patients
with potential for a better outcome.
In this study, we show data that identical mutations in
tumors from different organs might have different implica-
tions for therapy, supporting the concept of organ-specific
trial designs, as opposed to mutation-specific designs. In
addition, these data suggest that it is reasonable to consider
VeriStrat “good” NSCLC patients whose tumors have wild-
type EGFR or KRAS mutations for EGFR-targeted therapies.
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